Research programme: respiratory syncytial virus infections - Arana TherapeuticsAlternative Names: EGX-220; Research programme: RSV infections - Arana Therapeutics
Latest Information Update: 24 Aug 2009
Price : $50 *
At a glance
- Originator EvoGenix
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
- 06 Mar 2007 Antibody is still in development for respiratory syncytial virus in Australia.
- 08 Mar 2006 Preclinical trials in Respiratory syncytial virus infections in Australia (unspecified route)